← All Thc Therapeutics, INC filings

Thc Therapeutics, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
THCT
Thc Therapeutics, INC
10-Q: THC Therapeutics Reports Q3 2024 Results, Cites Ongoing Development of dHydronator
THC Therapeutics reported its financial results for the quarter ended April 30, 2024, highlighting a net income of $104,622, despite ongoing operating losses and a going concern qualification.
OTC.Pink
THCT
Thc Therapeutics, INC
10-Q: THC Therapeutics Reports Q2 2024 Results: Focus Remains on dHydronator Development
THC Therapeutics, Inc. reports its financial results for the quarter ended January 31, 2024, highlighting ongoing efforts to develop its dHydronator product amid going concern uncertainties.
OTC.Pink
THCT
Thc Therapeutics, INC
10-Q: THC Therapeutics Reports Q1 2024 Results: Minimal Revenue, Reduced Operating Loss, and Ongoing Going Concern Concerns
THC Therapeutics reports no revenue for Q1 2024, but manages to decrease its operating loss compared to the same period last year, while still facing substantial doubt about its ability to continue as a going concern.